Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-label, Single Arm, Clinical Study to Evaluate Efficacy, Safety and Tolerability of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT05414175 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT05414175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05414175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-label, Single Arm, Clinical Study to Evaluate Efficacy, Safety and Tolerability of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 3
Overall status
Completed
Start date
August 19, 2022
Completion date
December 11, 2025
Enrollment
38 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

cardiomyopathy, hypertrophic obstructive